UM: Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

UM: Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

An international phase III clinical trial evaluating the drug Arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) has reached full enrollment, as reported by a University of Miami Miller School of Medicine researcher. The current phase III trial builds upon the results of a prior phase II trial that enrolled patients with a rapidly progressive, rare genetic form of ALS.

Full Story

Related posts

UCF Researchers Make Super Stretchable E-Material Using Kirigami, Nanotechnology

By combining the ancient Japanese art of paper cutting with nanotechnology, University of Central Florida…

FAMU Announces $1.2 Million Program To Train Students To Help Children with Disabilities

Florida A&M University (FAMU) School of Allied Health Sciences’, divisions of Physical Therapy and Occupational Therapy have been awarded $1.2…

UWF one step closer to addressing high-tech workforce demand through Triumph Gulf Coast proposal

Designed to address shortages in additive and advanced manufacturing and cybersecurity, the UWF project received…